Solriamfetol
Centrally Acting Sympathomimetics
Sold as SUNOSI
- Drug class
- Centrally Acting Sympathomimetics
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 6
Overview
Solriamfetol is an active pharmaceutical ingredient in the Centrally Acting Sympathomimetics group (N06BA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | August 15, 2025 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
| EU European Union | EMA | 1 | May 27, 2026 |
GBUnited Kingdom· MHRA
3 products
Uses
Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).
How to take
CACanada· Health Canada
2 products
Uses
SUNOSI® (solriamfetol) is indicated for: • The treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. • The treatment of excessive daytime sleepiness in adult patients with obstructive sleep apnea (OSA). SUNOSI is not indicated to treat the underlying airway obstruction in patients with OSA.
, with continuous positive airway pressure (CPAP)), for an adequate period of time should be made, prior to initiating treatment with SUNOSI for excessive sleepiness. Primary OSA therapy for the underlying airway obstruction should be maintained during treatment with SUNOSI.
SUNOSI is not a substitute for primary OSA therapy. 1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatrics (>65 years of age): Limited data are available from patients 65 years of age or older.
4 WARNINGS AND Precautions, Special Populations, Geriatrics >65 years).
EUEuropean Union· EMA
1 product
Uses
Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).
How to take
Drug interactions
Known interactions involving Solriamfetol. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB432520049 · revised August 15, 2025
- [2]Health Canada (DPD) · 02515814 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/004893 · revised May 27, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.